Zydus Cadila has received final USFDA approval to market Doxazosin tablets, used for treatment of high blood pressure and urinary retention associated with enlargement of the prostate gland. The company will market the drug in strengths of 1 mg, 2 mg, 4 mg, and 8 mg. The drug is used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia. The company has also received tentative approval to market Lurasidone Hydrochloride Tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
Both Doxazosin tablets and Lurasidone Hydrochloride tablets will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
Company Profile : Cadila Healthcare Ltd
Leave a Reply